Lyell Immunopharma (LYEL) EBITDA Margin (QoQ) (2020 - 2026)
Lyell Immunopharma (LYEL) EBITDA Margin (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Lyell Immunopharma | 326.39 Mn | 326.39 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 102.96 Mn |
| Mar 31, 2026 | -8.57 Mn |
| Dec 31, 2025 | -187.90 Mn |
| Sep 30, 2025 | 34.09 Mn |
| Jun 30, 2025 | 23.03 Mn |
| Mar 31, 2025 | 100.91 Mn |
| Dec 31, 2024 | -168.01 Mn |
| Sep 30, 2024 | 24.78 Mn |
| Jun 30, 2024 | 145.61 Mn |
| Mar 31, 2024 | -139.47 Mn |
| Dec 31, 2023 | -22.16 Mn |
| Sep 30, 2023 | 793,659.00 |
| Jun 30, 2023 | -14.79 Mn |
| Mar 31, 2023 | -9.62 Mn |
| Dec 31, 2022 | 221.45 Mn |
| Sep 30, 2022 | -221.45 Mn |
| Jun 30, 2022 | 1.23 Mn |
| Mar 31, 2022 | -1.07 Mn |
| Dec 31, 2021 | 9,988.00 |
| Sep 30, 2021 | 60,168.00 |